Clinical Trials
15 trialsNCT03401060 2026-03-31
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT04681105 2026-01-28
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
Phase 1 Completed
NCT00769587 2025-09-22
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Centre Hospitalier Universitaire, Amiens
Completed
NCT00449748 2025-05-01
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03739606 2020-12-17
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT02441166 2019-07-15
EvaTryMS
University Hospital, Toulouse
Phase NA Completed
NCT01807598 2019-01-29
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Stanford University
Phase 2 Completed
NCT00233454 2018-09-20
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Stanford University
Phase 2 Completed
NCT02415608 2018-09-20
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
Stanford University
Phase 2 Terminated
NCT01297777 2016-08-29
Imatinib in KIT-negative Systemic Mastocytosis
Hospital Virgen de la Salud
Phase 4 Completed
NCT01602939 2016-08-29
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Hospital Virgen de la Salud
Phase 2/3 Unknown
NCT01920204 2015-01-19
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
Phase 2 Unknown
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00918931 2011-11-04
Obatoclax for Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00979160 2009-09-18
Evaluation of Response of Dasatinib to Treat Mastocytosis
Federico II University
Phase 2 Unknown